Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195408 | 1.00 | EGLN1 (0.39) | EGLN1DHODHIDO1MALT1NAMPT | |
| SCHEMBL195661 | 0.94 | IDO1 (0.36) | EGLN1DHODHIDO1NAMPTGPR6 | |
| SCHEMBL29416604 | 0.94 | IDO1 (0.36) | EGLN1DHODHIDO1NAMPTGPR6 | |
| SCHEMBL29416585 | 0.93 | IDO1 (0.36) | EGLN1DHODHIDO1MALT1NAMPT | |
| SCHEMBL516589 | 0.93 | IDO1 (0.36) | EGLN1DHODHIDO1MALT1NAMPT | |
| SCHEMBL29416550 | 0.91 | DHODH (0.40) | DHODHIDO1MALT1NAMPTCNR1 | |
| SCHEMBL195314 | 0.91 | DHODH (0.40) | DHODHIDO1MALT1NAMPTCNR1 | |
| SCHEMBL30078383 | 0.91 | DHODH (0.41) | EGLN1DHODHMALT1GCKKCNH2 | |
| SCHEMBL563173 | 0.91 | DHODH (0.41) | EGLN1DHODHMALT1GCKKCNH2 | |
| SCHEMBL11893160 | 0.88 | DHODH (0.40) | EGLN1DHODHMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056008-A1 | PYRIPYROPENE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119613426-A | Pyripyropene derivative, composition and application thereof | 青岛清原化合物有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240382454-A1 | ANTIPARASITIC ISOXAZOLINE COMPOUNDS, LONG-ACTING INJECTABLE FORMULATIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-11-21 | — | — | US | disclosed |
| US-12083100-B1 | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-2699563-B3 | NOVEL PESTICIDAL PYRAZOLE COMPOUNDS | BASF SE (DE) | 2024-06-12 | — | — | EP | disclosed |
| US-11497732-B2 | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-114573573-A | Antiparasitic isoxazoline compounds, long-acting injectable formulations containing them, methods and uses thereof | 勃林格殷格翰动物保健美国公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-109068651-B | Antiparasitic isoxazoline compounds, long-acting injectable formulations containing them, methods and uses thereof | 勃林格殷格翰动物保健美国公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083100-B1 | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof | IL17A, MMP17, MMP1 | EGLN1 879/4885DHODH 3577/4885IDO1 32/4885 |
| US-20240382454-A1 | ANTIPARASITIC ISOXAZOLINE COMPOUNDS, LONG-ACTING INJECTABLE FORMULATIONS COMPRISING THEM, METHODS AND USES THEREOF | IL17A, MMP17, MMP1 | EGLN1 879/4885DHODH 3577/4885IDO1 32/4885 |
| US-11497732-B2 | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof | IL17A, MMP17, MMP1 | EGLN1 879/4885DHODH 3577/4885IDO1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.